Michael Ryan - Kiromic Biopharma Chief Officer
Insider
Michael Ryan is Chief Officer of Kiromic Biopharma
Age | 56 |
Phone | 832 968 4888 |
Web | https://www.kiromic.com |
Michael Ryan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Ryan against Kiromic Biopharma stock is an integral part of due diligence when investing in Kiromic Biopharma. Michael Ryan insider activity provides valuable insight into whether Kiromic Biopharma is net buyers or sellers over its current business cycle. Note, Kiromic Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kiromic Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Ryan over a month ago Acquisition by Michael Ryan of 361 shares of Otis Worldwide subject to Rule 16b-3 | ||
Michael Ryan over six months ago Disposition of 130 shares by Michael Ryan of Otis Worldwide at 90.97 subject to Rule 16b-3 | ||
Michael Ryan over a year ago Exercise or conversion by Michael Ryan of 349 shares of Otis Worldwide subject to Rule 16b-3 | ||
Michael Ryan over a year ago Exercise or conversion by Michael Ryan of 349 shares of Otis Worldwide subject to Rule 16b-3 |
Kiromic Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.9194) % which means that it has lost $0.9194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.2981) %, meaning that it created substantial loss on money invested by shareholders. Kiromic Biopharma's management efficiency ratios could be used to measure how well Kiromic Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kiromic Biopharma currently holds 9.41 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Kiromic Biopharma has a current ratio of 1.32, which is within standard range for the sector. Note, when we think about Kiromic Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
Nandan BS | Immix Biopharma | 63 | |
Steen Knudsen | Allarity Therapeutics | 64 | |
Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
James JD | Allarity Therapeutics | 55 | |
Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
Claus Pedersen | Allarity Therapeutics | 52 | |
JD MBA | Immix Biopharma | N/A | |
LaBella MS | ZyVersa Therapeutics | 66 | |
Waldemar Priebe | Cns Pharmaceuticals | N/A | |
CPA CTP | Cns Pharmaceuticals | 44 | |
Gabriel BA | Immix Biopharma | 38 | |
Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 60 | |
MBA IV | Enveric Biosciences | 68 | |
MD FAAAAI | Palisade Bio | N/A | |
John CPA | Unicycive Therapeutics | 63 | |
Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
Joan Brown | Allarity Therapeutics | 70 | |
Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
Jason Davis | Virax Biolabs Group | 53 | |
Sharon McBrayer | Palisade Bio | N/A |
Management Performance
Return On Equity | -11.3 | ||||
Return On Asset | -0.92 |
Kiromic Biopharma Leadership Team
Elected by the shareholders, the Kiromic Biopharma's board of directors comprises two types of representatives: Kiromic Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kiromic. The board's role is to monitor Kiromic Biopharma's management team and ensure that shareholders' interests are well served. Kiromic Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kiromic Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Ryan, Chief Officer | ||
Leonardo Mirandola, Chief Officer | ||
JD CPA, CEO Director | ||
Daniel Clark, Chief Officer | ||
MD PharmD, Chief Staff |
Kiromic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kiromic Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -11.3 | ||||
Return On Asset | -0.92 | ||||
Current Valuation | 9.55 M | ||||
Shares Outstanding | 1.18 M | ||||
Shares Owned By Insiders | 3.91 % | ||||
Shares Owned By Institutions | 68.00 % | ||||
Number Of Shares Shorted | 45.74 K | ||||
Price To Book | 15.11 X | ||||
EBITDA | (29.44 M) | ||||
Net Income | (34.73 M) |
Pair Trading with Kiromic Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HP Inc to buy it.
The correlation of HP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HP Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |